In San Diego, DexCom, Inc. (NASDAQ: DXCM), a leading glucose biosensing company, revealed the addition of Glenn Boehnlein to its Board of Directors on September 10, 2026. Boehnlein brings over 20 years of expertise in the medical technology sector, having served as Vice President and CFO at Stryker Corporation, a top player in the industry. This move underscores DexCom's strategic focus on strengthening its leadership team.